Abstract
Background Development of mucosal adjuvants to elicit immunity in the female genital tract may have important implications for the development of vaccines to counter sexually transmitted infections. We have recently documented the vaginal adjuvant effect of the TLR9 agonist CpG-ODN, and a non-TLR targeting molecule α galactosylceramide (α-GalCer), an invariant natural killer T cell ligand, for induction of protective immunity in the murine female genital tract.
Highlights
Development of mucosal adjuvants to elicit immunity in the female genital tract may have important implications for the development of vaccines to counter sexually transmitted infections
AIDS Vaccine 2009 Anna Laura Ross Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf
Observed in the vagina of the CpG-ODN treated mice. This was concomitant with a higher degree of inflammation in the vaginal mucosa of the CpG-ODN group compared to that of the α-GalCer group. These results indicate that there is a group of common genes that correlate with the adjuvanticity of CpG-ODN and α-GalCer in the vagina and the draining lymph nodes, and that the non TLR/MyD88 targeting adjuvant α-GalCer induces less local inflammatory reactions in the murine vagina compared to the TLR/MyD88 targeting adjuvant CpG-ODN
Summary
Correlate of local adjuvanticity and inflammation for experimental vaginal adjuvants in mice. Address: 1The Swedish Institute of Infectious Disease Control, Karolinska Inst., Stockholm, Sweden, 2Department of Clinical Pathology and Cytology, Sahlgrenska Hospital, Gothenburg, Sweden and 3Department of Microbiology & Immunology, Institute of Biomedicine, University of Gothenburg, Göthenburg, Sweden. Published: 22 October 2009 Retrovirology 2009, 6(Suppl 3):P16 doi:10.1186/1742-4690-6-S3-P16. AIDS Vaccine 2009 Anna Laura Ross Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
